Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Barbara J Brandhuber"'
Autor:
Wen-I Wu, Walter C Voegtli, Hillary L Sturgis, Faith P Dizon, Guy P A Vigers, Barbara J Brandhuber
Publikováno v:
PLoS ONE, Vol 5, Iss 9, p e12913 (2010)
AKT1 (NP_005154.2) is a member of the serine/threonine AGC protein kinase family involved in cellular metabolism, growth, proliferation and survival. The three human AKT isozymes are highly homologous multi-domain proteins with both overlapping and d
Externí odkaz:
https://doaj.org/article/deb7442d250247b78775ee4e8843f54a
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRET
Externí odkaz:
https://doaj.org/article/c9aadc1f6bbc44acba731c2a7dcb7aef
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srushti Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/5da51ab03db947f7a3ffd0a6118bb43a
Autor:
Loredana Puca, Michele S. Dowless, Carmen M. Perez-Ferreiro, Maria Jesus Ortiz-Ruiz, Gregory P. Donoho, Andrew Capen, Lysiane Huber, Sarah M. Bogner, Dongling Fei, Jason R. Manro, Chun Ping Yu, Wei Guo Xu, Rui Wang, Shuang Chen, Mark A. Hicks, Parisa Zolfaghari, Andrew Faber, Raymond Gilmour, Monica D. Ramstetter, Matthew T. Chang, Maria Jose Lallena, Xuequian Gong, David M. Hyman, Lillian M. Smyth, Barbara J. Brandhuber, Barry S. Taylor, Anke Klippel
Publikováno v:
Cancer Research. 83:P4-08
Background Phosphoinositide 3-kinase alpha (PI3Kα) H1047R mutations are activating oncogenic events that occur in ~15% of breast cancers (BC). Early generation PI3Kα inhibitors target both wild-type (WT) and mutant PI3Kα and, as a result, their ef
Autor:
David M. Hyman, S. Michael Rothenberg, Steve Andrews, Barry S. Taylor, Jaclyn F. Hechtman, Michael F. Berger, Philip Jonsson, Alison M. Schram, Bethany Hanusch, Sandeep Raj, Ryma Benayed, Maurizio Scaltriti, Dorothea N. Douglas-Lindsay, Paul R. Gordon, Lance A. Wollenberg, Walter E. DeWolf, Francis X. Sullivan, Tony H. Morales, Andrew Parker, Wen-I Wu, Robyn Hamor, Shannon L. Winski, Karyn S. Bouhana, Paul D. Larsen, Barbara J. Brandhuber, Gabrielle R. Kolakowski, Veronique Lauriault, Steve Smith, Kevin Ebata, Brian B. Tuch, Nora Ku, James F. Blake, Ramamoorthy Nagasubramanian, Alexander Drilon
Supplementary Methods Supplementary References Supplementary Figure 1. Effect of acquired resistance mutations on TRK inhibitor activity. Supplementary Figure 2. Further characterization of LOXO-195 inhibitory activity against acquired resistance mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5cf7abc92430333d360a2e3d9ce4f70
https://doi.org/10.1158/2159-8290.22532260
https://doi.org/10.1158/2159-8290.22532260
Autor:
Eli Wallace, Kevin Koch, James D. Winkler, Patrice A. Lee, Joe Lyssikatos, Brian Hurley, Allison Marlow, Stefan Gross, Barbara J. Brandhuber, Darin Smith, Janet Parry, Ron J. Evans, Heidi Colwell, Josh Ballard, Bryan A. Bernat, Vivienne Marsh, Tammie C. Yeh
Supplementary Data, Yeh, et al. from Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb220f9585897004967629e2407f636
https://doi.org/10.1158/1078-0432.22441213.v1
https://doi.org/10.1158/1078-0432.22441213.v1
Autor:
Eli Wallace, Kevin Koch, James D. Winkler, Patrice A. Lee, Joe Lyssikatos, Brian Hurley, Allison Marlow, Stefan Gross, Barbara J. Brandhuber, Darin Smith, Janet Parry, Ron J. Evans, Heidi Colwell, Josh Ballard, Bryan A. Bernat, Vivienne Marsh, Tammie C. Yeh
Purpose: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics. We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406a4a31b0cf89e0543cd3f66dfd4a9e
https://doi.org/10.1158/1078-0432.c.6518341.v1
https://doi.org/10.1158/1078-0432.c.6518341.v1
Autor:
Eliana B Gomez, Kevin Ebata, Hetal S Randeria, Mary S Rosendahl, Ernst Peder Cedervall, Tony H Morales, Lauren M Hanson, Nicholas E Brown, Xueqian Gong, Jennifer Rachelle Stephens, Wenjuan Wu, Isabel Lippincott, Karin S. Ku, Richard A Walgren, Paolo B Abada, Joshua A Ballard, Charles K Allerston, Barbara J Brandhuber
Publikováno v:
Blood.
Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell driven malignancies. However, approved covalent BTK inhibitors (cBTKi) are associated with treatment limitations due to off-target side effects, sub
Autor:
Joshua A. Ballard, Kevin Ebata, Hetal S. Randeria, Garrett Tinline, Thomas Lee, Lauren M. Hanson, John A. Latham, E. Peder Cedervall, Jenny Chong, Kyle B. Del Valle, Bernard C. Collins, Tony H. Morales, Thomas C. Benedict, Marc A. Schureck, Ethan T. Bender, Christopher Mendoza, David Molina, Meagan Nakamoto, Hsiao-Chiao Shiah, Hao Xu, Alfonso Espada, Leticia Cano, Charles K. Allerston, Paul Schnier, Barbara J. Brandhuber
Publikováno v:
Cancer Research. 83:2780-2780
Covalent Bruton tyrosine kinase inhibitors (cBTKi) have transformed the treatment of B cell malignancies. Despite the efficacy of cBTKi, treatment failure often occurs through development of resistance or intolerance. Pirtobrutinib, a highly selectiv
Autor:
Andrew J, Kavran, Scott A, Stuart, Kristyn R, Hayashi, Joel M, Basken, Barbara J, Brandhuber, Natalie G, Ahn
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 119(12)
Patients with melanoma receiving drugs targeting BRAFV600E and mitogen-activated protein (MAP) kinase kinases 1 and 2 (MEK1/2) invariably develop resistance and face continued progression. Based on preclinical studies, intermittent treatment involvin